{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 447822020
| IUPAC_name = 3-[(pyridin-3-yl)carbonyloxy]-2,2-bis({[(pyridin-3-yl)carbonyloxy]methyl})propyl pyridine-3-carboxylate
| image = Niceritrol.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|niceritrol}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number =  
| ATC_prefix = C10
| ATC_suffix = AD01
| PubChem = 4476
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = F54EHJ34MV
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01754
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 4321

<!--Chemical data-->
| C=29 | H=24 | N=4 | O=8 
| molecular_weight = 556.523 g/mol
| smiles            = C1=CC(=CN=C1)C(=O)OCC(COC(=O)C2=CN=CC=C2)(COC(=O)C3=CN=CC=C3)COC(=O)C4=CN=CC=C4
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C29H24N4O8/c34-25(21-5-1-9-30-13-21)38-17-29(18-39-26(35)22-6-2-10-31-14-22,19-40-27(36)23-7-3-11-32-15-23)20-41-28(37)24-8-4-12-33-16-24/h1-16H,17-20H2
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = KUEUWHJGRZKESU-UHFFFAOYSA-N

}}

'''Niceritrol''' is a [[niacin]] derivative used as a [[hypolipidemic agent]]. It is an ester of pentaerythritol and nicotinic acid, has general properties similar to those of nicotinic acid (Nicotinamide), to which it is slowly hydrolysed. Niceritrol has been used as a lipid regulating drug in hyperlipidaemias and as a vasodilator in the treatment of peripheral vascular disease.<ref name="Owada">{{cite journal |author1=Owada A. |author2=Suda S |author3=Hata T. |title=Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial.|journal=Am J Med|volume=114 |issue=5 |pages=347â€“53|year=2003 |pmid=12714122 |doi= 10.1016/s0002-9343(02)01567-x|url=http://www.amjmed.com/article/S0002-9343(02)01567-X/abstract}}</ref><ref name=Micro>{{cite web|url=http://www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/CAA11B/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/10C889/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/evidencexpert.IntermediateToDocumentLink?docId=9258-x&contentSetId=30&title=Niceritrol&servicesTitle=Niceritrol|title=Niceritrol|author=Truven Health Analytics Inc.|work=Micromedexsolutions.com|date=May 8, 2008|accessdate=December 14, 2014}}</ref>

==References==
{{reflist}}
{{Lipid modifying agents}}

[[Category:Nicotinates]]


{{cardiovascular-drug-stub}}